FDA Approved New Prostate Cancer Therapy in July 2026
Patients with metastatic disease now have access to a targeted theranostic treatment approach.
Updated on Sept. 29, 2026 in Cancer
Live Poll
Do you trust targeted cancer therapies more than traditional chemotherapy for managing serious illness?
In July 2026, the FDA approved Pluvicto for the treatment of newly diagnosed metastatic prostate cancer. This therapy uses a method called theranostics to identify and target specific cancer cells.
Why it matters
Theranostics represents a shift toward more precise oncology, allowing for the direct treatment of cancer cells while potentially sparing surrounding healthy tissue. This approach is intended to improve outcomes by combining advanced diagnostic imaging with localized internal radiation.
The FDA approved Pluvicto in July 2026 based on its ability to deliver targeted radiation to patients whose cancer cells express the PSMA protein. The protocol consists of six IV injection sessions administered every six weeks.
The players
FDA
The federal agency responsible for regulating pharmaceuticals and approving new cancer therapies in the United States.
The details
The treatment functions through theranostics, a process that integrates diagnostic PET scanning with targeted therapy. First, patients receive a radioactive tracer to identify active cancer cells expressing the PSMA protein. Pluvicto then binds to that specific protein, delivering radiation directly to the tumor site to inhibit cancer cell growth.
Timeline
July 2026 marked the FDA approval of Pluvicto for metastatic prostate cancer.
Patients receive Pluvicto infusions once every six weeks.
Health Landscape
The introduction of Pluvicto aligns with the broader integration of PSMA-targeted therapies into the standard of care for advanced prostate cancer. This marks a departure from traditional systemic treatments by focusing on molecular-level targeting at institutions like Fox Chase Cancer Center.
If you or a loved one have been diagnosed with metastatic prostate cancer, ask your oncologist if your tumor cells express the PSMA protein. Understanding your eligibility for targeted therapies like Pluvicto is a conversation to have with your care team.
The takeaway
Pluvicto utilizes the PSMA protein to deliver precise radiation to advanced prostate cancer cells. Patients and their doctors should track potential side effects including fatigue and changes in blood counts throughout the six-session course of treatment.
Further reading
For more information on current treatment trends, visit the Cancer section.
Source note: This article includes information reported by 6abc Action News.
Live Poll
Do you trust targeted cancer therapies more than traditional chemotherapy for managing serious illness?
